Impact of early detection and steroid treatment on fetal ventricular heart rate and pacemaker implantation in anti-Ro/SSA positive congenital heart block

被引:0
|
作者
Sonesson, Sven-Erik [1 ,2 ]
Ambrosi, Aurelie [2 ]
Nordenstam, Felicia [1 ,3 ]
Eliasson, Hakan [1 ,3 ]
Wahren-Herlenius, Marie [2 ,4 ]
机构
[1] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden
[2] Karolinska Inst, Dept Med, Div Rheumatol, Stockholm, Sweden
[3] Karolinska Univ Hosp, Dept Pediat Cardiol, Stockholm, Sweden
[4] Univ Bergen, Dept Clin Sci, Broegelmann Res Lab, Bergen, Norway
基金
瑞典研究理事会;
关键词
anti-Ro/SSA; congenital heart block; fluorinated steroid; heart rate; pacemaker; treatment; PR INTERVAL; FETUSES; RISK; AUTOANTIBODIES; SURVEILLANCE; REGISTRY;
D O I
10.1111/aogs.14988
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Introduction We investigated the effects of timing of detection and transplacental fluorinated steroid treatment on ventricular heart rate (HR) and age at pacemaker implantation in fetal third-degree atrioventricular block (AVB). Material and Methods Twenty-five of 31 fetuses diagnosed with Ro/SSA autoantibody-positive AVB II-III at our tertiary fetal cardiology center (2000-2020) and AVB III as final feto-neonatal outcome were reviewed. Results AVB was detected approximately 5 weeks earlier in pregnancy if followed in a surveillance program compared to cases referred from primary care for bradycardia (20.6 [2.3] [mean (SD)] vs. 25.4 [3.2] weeks, p = 0.001). AVB detected before 24 weeks had higher HR than those detected later in gestation (63.3 [6.9] vs. 57.2 [6.9] bpm, p = 0.042), with a larger proportion having HR >60 bpm (80% vs. 33%, p = 0.041). The 17/25 cases that received treatment with fluorinated steroid were diagnosed earlier in gestation, with higher HR at diagnosis (61.7 [7.1] vs. 54.7 [6.3] bpm, p = 0.026), 1-2 weeks after diagnosis/treatment start, and before birth (65.4 [12.4] vs. 54.9 [5.7] bpm, p = 0.030) than untreated cases. Overall, 11 cases were commenced on betamimetics: three at diagnosis and eight at or after the examination made 1-2 weeks after diagnosis/treatment start, without any HR improvement. Two of 24 surviving babies were born preterm, and 4/24 received a neonatal pacemaker. Age at pacemaker implantation correlated significantly with HR before birth (Spearman R 0.57, p = 0.004), and fetuses with HR >60 bpm had a higher rate of pacemaker-free survival at three (90% vs. 40%, p = 0.018) and 12 months of age (80% vs. 13%, p = 0.002). The same trend was observed in pacemaker-free survival at 3 months of age in fluorinated steroid-treated compared to untreated cases (71% vs. 38%, ns). Conclusions Our data confirm that AVB III detected earlier in gestation have a higher HR, and suggest that this higher HR can be successfully maintained to the end of gestation in cases treated with fluorinated steroids. Fetuses with HR >60 bpm before birth had a lower rate of pacemaker implantation at 3 and 12 months of age.
引用
收藏
页码:2433 / 2441
页数:9
相关论文
共 45 条
  • [31] Maternal predictive factors for fetal congenital heart block in pregnant mothers positive for anti-SS-A antibodies
    Tsuboi, Hiroto
    Sumida, Takayuki
    Noma, Hisashi
    Yamagishi, Kazumasa
    Anami, Ai
    Fukushima, Kotaro
    Horigome, Hitoshi
    Maeno, Yasuki
    Kishimoto, Mitsumasa
    Takasaki, Yoshinari
    Nakayama, Masahiro
    Waguri, Masako
    Sago, Haruhiko
    Murashima, Atsuko
    MODERN RHEUMATOLOGY, 2016, 26 (04) : 569 - 575
  • [32] Low titer, isolated anti Ro/SSA 60 kd antibodies is correlated with positive pregnancy outcomes in women at risk of congenital heart block
    Marta Tonello
    Ariela Hoxha
    Elena Mattia
    Alessandra Zambon
    Silvia Visentin
    Alessia Cerutti
    Anna Ghirardello
    Ornella Milanesi
    Amelia Ruffatti
    Clinical Rheumatology, 2017, 36 : 1155 - 1160
  • [33] Increased risk of complete congenital heart block in infants born to women with hypothyroidism and anti-Ro and/or anti-La antibodies
    Spence, D
    Hornberger, L
    Hamilton, R
    Silverman, ED
    JOURNAL OF RHEUMATOLOGY, 2006, 33 (01) : 167 - 170
  • [34] Congenital Heart Block and Its Association With Anti-Ro and Anti-La Antibodies in Pregnancy: A Case Report of a Rare Entity and a Review of the Current Evidence
    Sapantzoglou, Ioakeim
    Fasoulakis, Zacharias
    Daskalakis, George
    Theodora, Marianna
    Antsaklis, Panagiotis
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [35] Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: A review of published literature and registered clinical trials
    Gleicher, Norbert
    Elkayam, Uri
    AUTOIMMUNITY REVIEWS, 2013, 12 (11) : 1039 - 1045
  • [36] Anti-Ro/SSA-p200 antibodies in the prediction of congenital heart block. An Italian multicentre cross-sectional study on behalf of the "Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA) Group"
    Scarsi, M.
    Radice, A.
    Pregnolato, F.
    Ramoni, V.
    Grava, C.
    Bianchi, L.
    Gerosa, M.
    Mosca, M.
    Ghirardello, A.
    Tani, C.
    Motta, M.
    Quinzanini, M.
    Tincani, A.
    Ruffatti, A.
    Migliorini, P.
    Doria, A.
    Meroni, P. L.
    Brucato, A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (06) : 848 - 854
  • [37] Prevention of complete heart block in children of mothers with anti-SSA/Ro and anti-SSB/La autoantibodies: detection and treatment of first-degree atrioventricular block
    Mevorach, Dror
    Elchalal, Uriel
    Rein, Azaria J. J. T.
    CURRENT OPINION IN RHEUMATOLOGY, 2009, 21 (05) : 478 - 482
  • [38] A combination therapy to treat second-degree anti-Ro/La-related congenital heart block. A strategy to avoid stable third-degree heart block?
    Ruffatti, A.
    Milanesi, O.
    Chiandetti, L.
    Cerutti, A.
    Gervasi, M. T.
    De Silvestro, G.
    Pengo, V.
    Punzi, L.
    LUPUS, 2012, 21 (06) : 666 - 671
  • [39] Fetal ventricular rate in case of congenital complete heart block is increased by ritodrine. Case report
    Koike, T
    Minakami, H
    Shiraishi, H
    Sato, I
    JOURNAL OF PERINATAL MEDICINE, 1997, 25 (02) : 216 - 218
  • [40] ANTI-LA(SS-B) BUT NOT ANTI-RO(52)(SS-A) ANTIBODIES CROSS-REACT WITH LAMININ - A ROLE IN THE PATHOGENESIS OF CONGENITAL HEART-BLOCK
    LI, JM
    HORSFALL, AC
    MAINI, RN
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1995, 99 (03) : 316 - 324